The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder.

Slater et al. (2020) ran a multi-center trial with 158 kids and teens who have autism. Half got a low dose of fluoxetine each morning. Half got a look-alike placebo. The dose averaged 12 mg a day. The team watched for 16 weeks to see if repetitive behaviors shrank.

The drug group and the placebo group ended at the same spot. Repetitive behaviors did not drop more with fluoxetine. Side effects were mild, but there was no benefit to justify daily use.

Willemsen-Swinkels et al. (1998) once gave open-label fluoxetine to seven autistic teens. They saw small gains in stereotypy. That study used 20-80 mg and had no control group. The new trial used tighter methods and a lower dose, so the older positive signal likely came from placebo noise.

Bent et al. (2009) reviewed omega-3 pills for autism and also found no clear win. Together, the two papers warn that early, small, or uncontrolled studies can paint too bright a picture.

South et al. (2012) showed that kids with autism need extra trials to switch rules. That cognitive rigidity may not budge with a mild SSRI dose. The null drug result now matches the null EF-training results.

BCBAs can now tell families that low-dose fluoxetine is unlikely to help hand-flapping or lining up toys. Save clinic time for behavioral plans that have data behind them. If a doctor still prescribes, you can track behaviors and expect little change.